Lung Cancer Dispatch
Follow
Find tag "Japan"
4.4K views | +2 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

No Progression-Free or Overall Survival Benefit With Second- or Third-Line Erlotinib vs Docetaxel in EGFR-Unselected Japanese NSCLC Patients

No Progression-Free or Overall Survival Benefit With Second- or Third-Line Erlotinib vs Docetaxel in EGFR-Unselected Japanese NSCLC Patients | Lung Cancer Dispatch | Scoop.it

"In a Japanese phase III trial (DELTA) reported in the Journal of Clinical Oncology, Kawaguchi et al found that erlotinib (Tarceva) was associated with no progression-free survival or overall survival advantage as second- or third-line therapy in EGFR-unselected patients with non–small cell lung cancer.


"In this open-label trial, 301 patients with stage IIIB or IV NSCLC, previous treatment with one or two chemotherapy regimens, evaluable or measurable disease, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were randomly assigned between August 2009 and July 2012 to erlotinib at 150 mg daily (n = 150) or docetaxel at 60 mg/m2every 3 weeks (n = 151). The primary endpoint was progression-free survival. In total, 109 patients (73%) in the erlotinib group and 90 (60%) in the docetaxel group had EGFR wild-type disease. Study treatment was third line in 19% and 14%, respectively."


Editor's note: This clinical trial tested a drug called erlotinib (brand name Tarceva), which is already known to be an effective treatment for lung cancer patients whose tumors have mutations in the EGFR gene. However, in this trial, the scientists were interested in whether erlotinib might help all patients, regardless of whether EGFR is mutated. The results show that erlotinib is no more effective than chemo for patients without EGFR mutations. But we recently posted another story about a protein test that may predict whether a patient without EGFR mutations might benefit from erlotinib treatment: http://www.cancercommons.org/news/proteomic-signature-for-egfr-inhibitor-therapy-predicts-survival-benefit-of-second-line-chemotherapy-vs-erlotinib-in-nsclc/.

Cancer Commons's insight:

The ASCO Post  |  May 27, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Amrubicin and Cisplatin Inferior to Irinotecan Regimen for Small-Cell Lung Cancer

Amrubicin and Cisplatin Inferior to Irinotecan Regimen for Small-Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

"A combination of amrubicin and cisplatin was inferior to irinotecan and cisplatin in chemotherapy-naïve patients with extensive disease small-cell lung cancer (SCLC) in a phase III trial conducted in Japan. The irinotecan regimen remains the standard treatment for these patients in that country.


"SCLC accounts for 13% of all new cases of lung cancer, and more than half of those patients present with extensive disease. Though SCLC can be very sensitive to chemotherapy, authors of the new study wrote that “rapid emergence of clinical drug resistance has resulted in poor prognosis, with almost all such patients dead with 2 years of initial diagnosis.” Investigators led by Miyako Satouchi, MD, PhD, of the Hyogo Cancer Center in Akashi, Japan, tested the amrubicin and cisplatin combination against irinotecan and cisplatin in 284 patients; results were published online ahead of print on March 17 in the Journal of Clinical Oncology."

Cancer Commons's insight:

Cancer Network  |  Apr 23, 2014

more...
No comment yet.